Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$28.92
+0.5%
$24.23
$21.97
$32.33
$1.23B1.54316,656 shs231,445 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.06
$4.65
$13.13
$1.10B1.471.10 million shs19.38 million shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$16.84
+0.3%
$16.61
$6.66
$25.00
$1.13B1.6196,890 shs136,671 shs
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$9.54
$8.53
$5.48
$14.23
$354.92M1.31822,700 shs1.16 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
+0.46%+5.35%+23.56%-3.12%+24.66%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%+0.69%+0.34%+61.59%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
+0.30%+1.75%+4.99%-21.46%+135.52%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artivion, Inc. stock logo
AORT
Artivion
1.3556 of 5 stars
1.61.00.00.02.52.51.9
Paragon 28, Inc. stock logo
FNA
Paragon 28
1.0068 of 5 stars
1.15.00.00.00.03.30.6
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
0.8161 of 5 stars
0.00.00.04.22.03.30.0
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
3.17
Buy$31.408.58% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
0.00
N/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SPNE, AORT, PLSE, and FNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Artivion, Inc. stock logo
AORT
Artivion
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/6/2025
Artivion, Inc. stock logo
AORT
Artivion
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.00
5/6/2025
Artivion, Inc. stock logo
AORT
Artivion
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
2/25/2025
Artivion, Inc. stock logo
AORT
Artivion
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $30.00
2/25/2025
Artivion, Inc. stock logo
AORT
Artivion
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$34.00 ➝ $32.00
(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$390.08M3.17$0.79 per share36.78$6.87 per share4.21
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K1,618.42N/AN/A$0.81 per share20.79
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$191.45M1.85N/AN/A$8.57 per share1.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
-$30.69M-$0.50N/A57.84N/A-0.22%5.15%1.91%N/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%5/14/2025 (Estimated)
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21MN/A0.00N/AN/A-96.89%-74.83%N/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
-$54.35M-$1.77N/AN/AN/A-28.22%-22.16%-17.09%N/A

Latest SPNE, AORT, PLSE, and FNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$0.19N/AN/AN/A$69.62 millionN/A
5/8/2025Q1 2025
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A-$0.25N/A-$0.25N/AN/A
5/5/2025Q1 2025
Artivion, Inc. stock logo
AORT
Artivion
$0.12$0.06-$0.06-$0.01$94.81 million$98.98 million
3/6/2025Q4 2024
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$0.12-$0.13-$0.01-$0.13$70.81 million$71.75 million
2/24/2025Q4 2024
Artivion, Inc. stock logo
AORT
Artivion
$0.12-$0.39-$0.51-$0.39$100.82 million$97.31 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
0.71
1.88
1.33
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
11.93
11.93
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.09
3.18
1.65

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
70.81%

Insider Ownership

CompanyInsider Ownership
Artivion, Inc. stock logo
AORT
Artivion
7.60%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
71.50%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
9.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,30042.70 million38.52 millionOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
14067.27 million17.53 millionOptionable
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
52337.20 million33.74 millionOptionable

Recent News About These Companies

Corewell Health adds 7D Flash
Spine Biologics Market Size to Achieve USD 6.95 Bn by 2033
The 2024 Medtech Big 100: The world’s largest medical device companies
Q2 2024 Orthofix Medical Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artivion stock logo

Artivion NYSE:AORT

$28.92 +0.15 (+0.52%)
As of 05/13/2025 03:59 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Pulse Biosciences stock logo

Pulse Biosciences NASDAQ:PLSE

$16.84 +0.05 (+0.30%)
Closing price 05/13/2025 04:00 PM Eastern
Extended Trading
$17.03 +0.19 (+1.12%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

SeaSpine stock logo

SeaSpine NASDAQ:SPNE

As of January 4, 2023, SeaSpine Holdings Corporation was acquired by Orthofix Medical Inc. SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.